Publicacións en colaboración con investigadores/as de University of Oxford (27)

2023

  1. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists

    Communications biology, Vol. 6, Núm. 1, pp. 376

2022

  1. Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 12

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway

    International Immunopharmacology, Vol. 89

2017

  1. Gefitinib and EGFR gene copy number aberrations in esophageal cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287

  2. Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with Neisseria meningitidis protein Mip

    Journal of Drug Delivery Science and Technology, Vol. 42, pp. 299-306

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 95, Núm. 5, pp. 1367-1377

  4. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

    PLoS Pathogens, Vol. 12, Núm. 7

2014

  1. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904

2009

  1. Proteomic analysis of HepaRG cells: A novel cell line that supports hepatitis B virus infection

    Journal of Proteome Research, Vol. 8, Núm. 1, pp. 118-122

  2. Proteomic analysis of integrin αIIbβ3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 10, pp. 1718-1726

2008

  1. A microtubule interactome: Complexes with roles in cell cycle and mitosis

    PLoS Biology, Vol. 6, Núm. 4, pp. 785-795

2007

  1. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein

    Molecular and Cellular Proteomics, Vol. 6, Núm. 3, pp. 548-564

  2. Biomarker discovery from uveal melanoma secretomes: Identification of gp100 and cathepsin D in patient serum

    Journal of Proteome Research, Vol. 6, Núm. 7, pp. 2802-2811

2006

  1. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: Involvement of G6f, a novel platelet Grb2-binding membrane adapter

    Proteomics, Vol. 6, Núm. 19, pp. 5332-5343

  2. Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara

    Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1764, Núm. 5, pp. 863-871

  3. Proteome analysis of signaling cascades in human platelets

    Blood Cells, Molecules, and Diseases, Vol. 36, Núm. 2, pp. 152-156

  4. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker

    International Journal of Cancer, Vol. 119, Núm. 5, pp. 1014-1022